On Aug. 13, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved TICOVACﾙ (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older.

TICOVACﾙis the only FDA-approved vaccine to help protect U.S. adults and children against the TBE virus when visiting or living in TBE endemic areas.